- Home
- KALA vs BOLD Comparison
KALA vs BOLD Comparison
Compare KALA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- BOLD
- Stock Information
- Founded
- KALA 2009
- BOLD 2018
- Country
- KALA United States
- BOLD United States
- Employees
- KALA N/A
- BOLD N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- KALA Health Care
- BOLD
- Exchange
- KALA Nasdaq
- BOLD Nasdaq
- Market Cap
- KALA 26.2M
- BOLD 30.3M
- IPO Year
- KALA 2017
- BOLD 2024
- Fundamental
- Price
- KALA $5.10
- BOLD $1.07
- Analyst Decision
- KALA Strong Buy
- BOLD Buy
- Analyst Count
- KALA 3
- BOLD 3
- Target Price
- KALA $14.00
- BOLD $4.00
- AVG Volume (30 Days)
- KALA 71.3K
- BOLD 363.5K
- Earning Date
- KALA 08-05-2025
- BOLD 08-11-2025
- Dividend Yield
- KALA N/A
- BOLD N/A
- EPS Growth
- KALA N/A
- BOLD N/A
- EPS
- KALA N/A
- BOLD N/A
- Revenue
- KALA N/A
- BOLD N/A
- Revenue This Year
- KALA N/A
- BOLD N/A
- Revenue Next Year
- KALA N/A
- BOLD N/A
- P/E Ratio
- KALA N/A
- BOLD N/A
- Revenue Growth
- KALA N/A
- BOLD N/A
- 52 Week Low
- KALA $2.92
- BOLD $1.00
- 52 Week High
- KALA $11.20
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- KALA 62.32
- BOLD N/A
- Support Level
- KALA $4.36
- BOLD N/A
- Resistance Level
- KALA $5.90
- BOLD N/A
- Average True Range (ATR)
- KALA 0.50
- BOLD 0.00
- MACD
- KALA 0.07
- BOLD 0.00
- Stochastic Oscillator
- KALA 61.50
- BOLD 0.00
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.